Recent fluctuations in the stock market have drawn investors’ attention to shares of Novo Nordisk A/S $NVO, which dropped by 9.8% to 380 Danish krone. This decline comes amid concerns regarding new weight loss pills introduced by competitor Eli Lilly & Co. $LLY. Such news raises questions about the future of bestselling drugs like Ozempic and their ability to maintain market positions in a rapidly evolving environment.

Novo Holdings, the principal shareholder of the pharmaceutical giant Novo Nordisk, continues to make its mark on the global financial landscape. According to its latest report, the company nearly doubled its annual revenue, reaching a record €8 billion in 2024. This impressive growth stems from increased investment profits tied to blockbuster drugs Wegovy and Ozempic.